Central Nervous System News and Research

RSS

Effective defense against HIV: Acne drug minocycline

Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating.

20 Mar 2010

InvestorSoup.com announces investment report featuring Somaxon Pharmaceuticals

InvestorSoup.com announces an investment report featuring Somaxon Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

19 Mar 2010

Penn Medicine, AstraZeneca collaborate to generate new AD drug candidates

The University of Pennsylvania and AstraZeneca today announced a new collaborative research agreement to make use of their respective talents and resources in an effort to bridge the transition from drug discovery to development.

19 Mar 2010

Acne drug prevents HIV breakout

18 Mar 2010

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

The Epilepsy Therapy Project, a non-profit organization dedicated to accelerating new therapies for people living with epilepsy, today released presentation highlights following its successful 2010 Epilepsy Pipeline Update Conference held in San Francisco. Sponsored by ETP, this conference brings together leading clinical investigators, emerging CNS companies and academic innovators with investors and business development partners to facilitate professional collaboration, funding and partnerships that will accelerate patient access to new treatments.

18 Mar 2010

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

It is announced today that CNS Network has purchased ALPHADAS®, Logos Technologies Inc’s early phase, e-source data capture system and site automation tools to accelerate and streamline its clinical trials. ALPHADAS is to be implemented in their Orange County Research Center, California, USA.

17 Mar 2010

StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

StockPreacher.com announces an investment report featuring ACADIA Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

17 Mar 2010

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Protalix BioTherapeutics, Inc. announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate in development for biodefense indications. The trial is designed to study the safety of PRX-105 by administering a bolus intravenous injection of PRX-105 in healthy volunteers.

17 Mar 2010

Researchers identify a novel way to study species-specific reproductive behavior

Researchers at the California Institute of Technology (Caltech) and the University of California, San Diego (UCSD) have discovered that injecting a simple hormone into leeches creates a novel way to study how hormones and the nervous system work together to produce species-specific reproductive behavior.

17 Mar 2010

ICON opens new office in Manila, Philippines

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it will expand its footprint in Asia-Pacific with the opening of an office in Manila, Philippines.

16 Mar 2010

BeaconEquity.com: STEM losses $5.2M in fourth-quarter of 2009

BeaconEquity.com announces an investment report featuring biotech company StemCells Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

16 Mar 2010

Minimal improvements made in survival rates of AYA population with cancer

Despite cancer survival rates increasing dramatically for children and older adults in the last 20 years, there has been minimal improvement in the survival rates in the Adolescent and Young Adult (AYA) population, an age range defined as 15 – 29 years by the presenters.

16 Mar 2010

Metabolic drugs top the list of prescription drug expenses for elderly Medicare beneficiaries

Purchases of cholesterol and diabetes prescription drugs by elderly Medicare beneficiaries reached nearly $19 billion in 2007 - about one-fourth of the approximately $82 billion spent for medications for the elderly, according to the latest AHRQ News and Numbers.

16 Mar 2010

Tel Aviv University researcher uses magic tricks to treat children with locomotor disabilities

It's often hard to motivate youngsters with physical disabilities. But a new approach from a Tel Aviv University researcher bridges the worlds of behavior and science to help kids with paralysis and motor dysfunction improve their physical skills and inner confidence -- using a trick up her sleeve called "magic."

16 Mar 2010

Positive results from Phase IIa epilepsy study of ICA-105665

Icagen, Inc. today reported positive results in its Phase IIa epilepsy study of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel agonist.

16 Mar 2010

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company’s approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix’s patent application, “Methods and Compositions for the Treatment of Neurological Disease,” which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain’s temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).

15 Mar 2010

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Johns Hopkins University's newly formed Brain Science Institute's NeuroTranslational Program has entered into a licensing agreement with pharmaceutical company Eisai Inc. to discover and develop small molecule glutamate carboxypeptidase II (GCPII) inhibitors.

15 Mar 2010

Eisai, Johns Hopkins University's BSI enter into licensing agreement for GCPII technology

Eisai Inc. today announces that it has entered into a licensing agreement with the Johns Hopkins University's Brain Science Institute related to Eisai's GCPII (glutamate carboxypeptidase II) technology.

12 Mar 2010

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat- (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

New molecule effective against lice

French medical researchers from the AP-HP (Henri Mondor Hospital and Avicenne Hospital) and Inserm (Unit 738 "Models and methods for therapeutic evaluation of chronic illnesses" and CIC 202, at Tours) have recently demonstrated the effectiveness of a new molecule in the fight against lice. Faced with the emergence of increasing resistance to conventional treatments by these parasites, this new medication represents a real therapeutic alternative which is effective in 95% of cases.

12 Mar 2010

Central Nervous System News and Research

Effective defense against HIV: Acne drug minocycline

InvestorSoup.com announces investment report featuring Somaxon Pharmaceuticals

Penn Medicine, AstraZeneca collaborate to generate new AD drug candidates

Acne drug prevents HIV breakout

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Researchers identify a novel way to study species-specific reproductive behavior

ICON opens new office in Manila, Philippines

BeaconEquity.com: STEM losses $5.2M in fourth-quarter of 2009

Minimal improvements made in survival rates of AYA population with cancer

Metabolic drugs top the list of prescription drug expenses for elderly Medicare beneficiaries

Tel Aviv University researcher uses magic tricks to treat children with locomotor disabilities

Positive results from Phase IIa epilepsy study of ICA-105665

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Eisai, Johns Hopkins University's BSI enter into licensing agreement for GCPII technology

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

New molecule effective against lice

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News